Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways.
about
Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@en
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@nl
type
label
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@en
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@nl
prefLabel
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@en
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@nl
P2093
P2860
P1433
P1476
Sodium orthovanadate overcomes ...... nd hypoxia-inducible pathways.
@en
P2093
Guangxin Li
Hongchi Jiang
Weidong Li
Wenjing Jiang
Xian Jiang
P2860
P356
10.1038/S41598-018-28010-Y
P407
P50
P577
2018-06-26T00:00:00Z